Investing.com -- Shares of Ascendis Pharma (NASDAQ:ASND) rose as much as 8.5% to a new high.
On January 20th RBC Capital updated its model based on new guidance from the company, raising its price target to $250 from $245.
According to RBC Capital, Ascendis Pharma outlined key goals for 2026 during a meeting with the firm. The company expects launch momentum for its Yorvipath drug to continue steadily throughout 2026 with no slowdown in patient additions.
Ascendis noted that the U.S. market remains largely underpenetrated, with 5,300 unique patients starting treatment versus a total addressable market of 70,000-90,000 patients. The company reported that the discontinuation rate for Yorvipath remains low.
The European opportunity is described as very meaningful, though the fragmented payer system requires time and discipline. Management indicated that the European total addressable market is significantly larger at 150,000-200,000 patients compared to 70,000-90,000 in the U.S. Ultimately, Ascendis believes revenue split may reach 60:40 U.S. to ex-U.S.
Regarding its next-generation weekly PTH treatment, Ascendis stated that Yorvipath will remain the gold standard during the titration phase, but 35-40% of patients, primarily stable ones, might choose a weekly option during the maintenance phase. The company has developed a novel TransCon technology that minimizes peak-to-trough excursion and is planning an expedited clinical development.
For its CNP product, Ascendis has a PDUFA date at the end of February. The company highlighted benefits beyond linear growth, particularly on arm span with GH combination.
On financial projections, Ascendis reiterated €500 million in operating cash flow for 2026 and over €5 billion in top-line revenue by 2030, compared to consensus estimates of approximately €3.5 billion. The company expects Yorvipath to ultimately be a €5-8 billion drug at peak.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.





























